New from NCI |
Cancer Research Starts Here |
|
|
We’re shining a spotlight on some of the researchers who’ve helped shape our understanding of cancer. Read their stories to learn more. |
For Kids with Medulloblastoma, Trial Suggests Radiation Can Be Tailored |
|
|
Read about the results of a large clinical trial that suggest that some kids may safely get less radiation without limiting their long-term survival. Others may still need the standard dose. |
Could a Diabetes Diagnosis Help Detect Pancreatic Cancer Early? |
|
|
Many studies have pointed to a link between new-onset diabetes and pancreatic cancer. Now, a number of large NCI-supported studies are testing ways to pick out those people whose diabetes might be a sign of early pancreatic cancer, when treatments may be more effective. |
Genetic Clues May Lead to Tailored Treatments for Rare Childhood Cancer
In children with rhabdomyosarcoma, the presence of mutations in several genes appears to be linked to a more aggressive form of the disease and a poorer chance of survival. Learn more about the international study that led to these findings. |
Annual Report to the Nation: Overall Cancer Death Rates Continue to Decline
A rapid decrease in deaths from lung cancer and melanoma has led to a continued drop in the rate of deaths from all cancers in the United States. This drop was seen in men and women of all racial and ethnic groups.
|
PDQ Updates |
Adult Non-Hodgkin Lymphoma Treatment
We’ve updated the targeted therapy section in our PDQ summary on the treatment of adult non-Hodgkin lymphoma (NHL). Treatment options were also updated for recurrent NHL and indolent, noncontiguous stage II, III, or IV NHL. |
FDA Approvals |
Daratumumab and Hyaluronidase-fihj
We’ve updated our drug summary on daratumumab and hyaluronidase-fihj (Darzalex Faspro) with a new Food and Drug Administration approval. The drug is now approved to be used together with pomalidomide and dexamethasone to treat adults who have received at least one prior treatment for multiple myeloma. |